Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Gut 2008;57:i-ii
Copyright © 2008 BMJ Publishing Group Ltd & British Society of Gastroenterology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Spiller, R.
Right arrow Articles by Simren, M.
PubMed
Right arrow Articles by Spiller, R.
Right arrow Articles by Simren, M.
Topic Collections
Right arrowRelevant Articles

Digest

Digest

Robin Spiller, editor, Magnus Simren, deputy editor

The first 150 words of the full text of this article appear below.


Once daily slow release mesalazine is equivalent to twice daily for the maintenance of remission in ulcerative colitis
Once daily dosing undoubtedly improves compliance, so this study, comparing once daily with twice daily dosing of mesalazine, is encouraging. Patients with mild to moderate acute ulcerative colitis achieving remission in a previous 8-week study of either 2.4 g once daily, 1.2 g twice daily or 4.8 g once daily were entered into the present open-labelled 12-month maintenance trial comparing 1.2 g twice daily with 2.4 g daily. Those failing to respond to the initial 8-week’s treatment were offered a further 8 weeks of 2.4 g twice daily and, if they then achieved remission, were also entered into the maintenance trial. Of 459 patients randomised, 213 required the additional 8 weeks at 4.8 g daily to achieve remission. Adverse events were equally distributed between the two groups. Only one serious adverse event was considered to be related to the study treatment. Remission rates at 12 months were similar for the . . . [Full text of this article]


Relevant Articles

Anti-inflammatory role of sympathetic nerves in chronic intestinal inflammation
R H Straub, F Grum, U Strauch, S Capellino, F Bataille, A Bleich, W Falk, J Schölmerich, and F Obermeier
Gut 2008 57: 911-921. [Abstract] [Full Text] [PDF]

Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis
A Walther, R Houlston, and I Tomlinson
Gut 2008 57: 941-950. [Abstract] [Full Text] [PDF]

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
M A Kamm, G R Lichtenstein, W J Sandborn, S Schreiber, K Lees, K Barrett, and R Joseph
Gut 2008 57: 893-902. [Abstract] [Full Text] [PDF]

Reduced {alpha}-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn’s disease
L A Simms, J D Doecke, M D Walsh, N Huang, E V Fowler, and G L Radford-Smith
Gut 2008 57: 903-910. [Abstract] [Full Text] [PDF]

Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia–reperfusion injury
G Serviddio, F Bellanti, R Tamborra, T Rollo, N Capitanio, A D Romano, J Sastre, G Vendemiale, and E Altomare
Gut 2008 57: 957-965. [Abstract] [Full Text] [PDF]

A prospective national study of acute fatty liver of pregnancy in the UK
M Knight, C Nelson-Piercy, J J Kurinczuk, P Spark, P Brocklehurst on behalf of UK Obstetric Surveillance System (UKOSS)
Gut 2008 57: 951-956. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & British Society of Gastroenterology